Genomic Classification of Cutaneous Melanoma

Andersen, 1993, Mutations in the neurofibromatosis 1 gene in sporadic malignant melanoma cell lines, Nat. Genet., 3, 118, 10.1038/ng0293-118

Ascierto, 2014, Clinical experience with ipilimumab 3 mg/kg: real-world efficacy and safety data from an expanded access programme cohort, J. Transl. Med., 12, 116, 10.1186/1479-5876-12-116

Azimi, 2012, Tumor-infiltrating lymphocyte grade is an independent predictor of sentinel lymph node status and survival in patients with cutaneous melanoma, J. Clin. Oncol., 30, 2678, 10.1200/JCO.2011.37.8539

Baade, 2012, Time trends and latitudinal differences in melanoma thickness distribution in Australia, 1990-2006, Int. J. Cancer, 130, 170, 10.1002/ijc.25996

Balch, 2009, Final version of 2009 AJCC melanoma staging and classification, J. Clin. Oncol., 27, 6199, 10.1200/JCO.2009.23.4799

Balch, 2010, Multivariate analysis of prognostic factors among 2,313 patients with stage III melanoma: comparison of nodal micrometastases versus macrometastases, J. Clin. Oncol., 28, 2452, 10.1200/JCO.2009.27.1627

Berger, 2012, Melanoma genome sequencing reveals frequent PREX2 mutations, Nature, 485, 502, 10.1038/nature11071

Bogunovic, 2009, Immune profile and mitotic index of metastatic melanoma lesions enhance clinical staging in predicting patient survival, Proc. Natl. Acad. Sci. USA, 106, 20429, 10.1073/pnas.0905139106

Brahmer, 2012, Safety and activity of anti-PD-L1 antibody in patients with advanced cancer, N. Engl. J. Med., 366, 2455, 10.1056/NEJMoa1200694

Brash, 2015, UV signature mutations, Photochem. Photobiol., 91, 15, 10.1111/php.12377

Brennan, 2013, The somatic genomic landscape of glioblastoma, Cell, 155, 462, 10.1016/j.cell.2013.09.034

Carter, 2012, Absolute quantification of somatic DNA alterations in human cancer, Nat. Biotechnol., 30, 413, 10.1038/nbt.2203

Carvajal, 2011, KIT as a therapeutic target in metastatic melanoma, JAMA, 305, 2327, 10.1001/jama.2011.746

Criscione, 2010, Melanoma thickness trends in the United States, 1988-2006, J. Invest. Dermatol., 130, 793, 10.1038/jid.2009.328

Curtin, 2005, Distinct sets of genetic alterations in melanoma, N. Engl. J. Med., 353, 2135, 10.1056/NEJMoa050092

Dasgupta, 1963, Malignant Melanoma of Unknown Primary Origin, Surg. Gynecol. Obstet., 117, 341

Draper, 1986, Second primary neoplasms in patients with retinoblastoma, Br. J. Cancer, 53, 661, 10.1038/bjc.1986.110

Dutton-Regester, 2014, A highly recurrent RPS27 5′UTR mutation in melanoma, Oncotarget, 5, 2912, 10.18632/oncotarget.2048

Eggermont, 2008, Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial, Lancet, 372, 117, 10.1016/S0140-6736(08)61033-8

Erdag, 2012, Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma, Cancer Res., 72, 1070, 10.1158/0008-5472.CAN-11-3218

Field, 2014, Recent developments in prognostic and predictive testing in uveal melanoma, Curr. Opin. Ophthalmol., 25, 234, 10.1097/ICU.0000000000000051

Frederick, 2014, Clinical profiling of BCL-2 family members in the setting of BRAF inhibition offers a rationale for targeting de novo resistance using BH3 mimetics, PLoS ONE, 9, e101286, 10.1371/journal.pone.0101286

Gershenwald, 2011, Sentinel-lymph-node biopsy for cutaneous melanoma, N. Engl. J. Med., 364, 1738, 10.1056/NEJMct1002967

Gold, 2014, PP6C hotspot mutations in melanoma display sensitivity to Aurora kinase inhibition, Mol. Cancer Res., 12, 433, 10.1158/1541-7786.MCR-13-0422

Hamid, 2013, Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma, N. Engl. J. Med., 369, 134, 10.1056/NEJMoa1305133

Helming, 2014, ARID1B is a specific vulnerability in ARID1A-mutant cancers, Nat. Med., 20, 251, 10.1038/nm.3480

Hodi, 2008, Major response to imatinib mesylate in KIT-mutated melanoma, J. Clin. Oncol., 26, 2046, 10.1200/JCO.2007.14.0707

Hodis, 2012, A landscape of driver mutations in melanoma, Cell, 150, 251, 10.1016/j.cell.2012.06.024

Horn, 2013, TERT promoter mutations in familial and sporadic melanoma, Science, 339, 959, 10.1126/science.1230062

Huang, 2013, Highly recurrent TERT promoter mutations in human melanoma, Science, 339, 957, 10.1126/science.1229259

Jayaraman, 2014, Mutational landscape of basal cell carcinomas by whole-exome sequencing, J. Invest. Dermatol., 134, 213, 10.1038/jid.2013.276

Ji, 2013, Vemurafenib synergizes with nutlin-3 to deplete survivin and suppresses melanoma viability and tumor growth, Clin. Cancer Res., 19, 4383, 10.1158/1078-0432.CCR-13-0074

Kirkwood, 1996, Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684, J. Clin. Oncol., 14, 7, 10.1200/JCO.1996.14.1.7

Krauthammer, 2012, Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma, Nat. Genet., 44, 1006, 10.1038/ng.2359

Küsters-Vandevelde, 2010, Activating mutations of the GNAQ gene: a frequent event in primary melanocytic neoplasms of the central nervous system, Acta Neuropathol., 119, 317, 10.1007/s00401-009-0611-3

Lawrence, 2013, Mutational heterogeneity in cancer and the search for new cancer-associated genes, Nature, 499, 214, 10.1038/nature12213

Lawrence, 2014, Discovery and saturation analysis of cancer genes across 21 tumour types, Nature, 505, 495, 10.1038/nature12912

Lopez, 2010, IDH1(R132) mutation identified in one human melanoma metastasis, but not correlated with metastases to the brain, Biochem. Biophys. Res. Commun., 398, 585, 10.1016/j.bbrc.2010.06.125

Lutzky, 2008, Dose-dependent, complete response to imatinib of a metastatic mucosal melanoma with a K642E KIT mutation, Pigment Cell Melanoma Res., 21, 492, 10.1111/j.1755-148X.2008.00475.x

Maertens, 2013, Elucidating distinct roles for NF1 in melanomagenesis, Cancer Discov., 3, 338, 10.1158/2159-8290.CD-12-0313

Mann, 2013, BRAF mutation, NRAS mutation, and the absence of an immune-related expressed gene profile predict poor outcome in patients with stage III melanoma, J. Invest. Dermatol., 133, 509, 10.1038/jid.2012.283

McArthur, 2013, Targeting oncogenic drivers and the immune system in melanoma, J. Clin. Oncol., 31, 499, 10.1200/JCO.2012.45.5568

Mihm, 1996, Tumor infiltrating lymphocytes in lymph node melanoma metastases: a histopathologic prognostic indicator and an expression of local immune response, Lab. Invest., 74, 43

Morton, 2014, Final trial report of sentinel-node biopsy versus nodal observation in melanoma, N. Engl. J. Med., 370, 599, 10.1056/NEJMoa1310460

Nikolaev, 2012, Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma, Nat. Genet., 44, 133, 10.1038/ng.1026

Nissan, 2014, Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence, Cancer Res., 74, 2340, 10.1158/0008-5472.CAN-13-2625

Noushmehr, 2010, Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma, Cancer Cell, 17, 510, 10.1016/j.ccr.2010.03.017

Pollock, 2003, High frequency of BRAF mutations in nevi, Nat. Genet., 33, 19, 10.1038/ng1054

Rakosy, 2013, Integrative genomics identifies gene signature associated with melanoma ulceration, PLoS ONE, 8, e54958, 10.1371/journal.pone.0054958

Ranzani, 2015, BRAF/NRAS wild-type melanoma, NF1 status and sensitivity to trametinib, Pigment Cell Melanoma Res., 28, 117, 10.1111/pcmr.12316

Robbins, 2013, Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells, Nat. Med., 19, 747, 10.1038/nm.3161

Robert, 2014, Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial, Lancet, 384, 1109, 10.1016/S0140-6736(14)60958-2

Santa Cruz, 1997, Differential expression of metallopanstimulin/S27 ribosomal protein in melanocytic lesions of the skin, J. Cutan. Pathol., 24, 533, 10.1111/j.1600-0560.1997.tb01457.x

Shields, 2007, Lack of extracellular signal-regulated kinase mitogen-activated protein kinase signaling shows a new type of melanoma, Cancer Res., 67, 1502, 10.1158/0008-5472.CAN-06-3311

Snyder, 2014, Genetic basis for clinical response to CTLA-4 blockade in melanoma, N. Engl. J. Med., 371, 2189, 10.1056/NEJMoa1406498

Sun, 2014, Discovery of AMG 232, a potent, selective, and orally bioavailable MDM2-p53 inhibitor in clinical development, J. Med. Chem., 57, 1454, 10.1021/jm401753e

2008, Comprehensive genomic characterization defines human glioblastoma genes and core pathways, Nature, 455, 1061, 10.1038/nature07385

2012, Comprehensive genomic characterization of squamous cell lung cancers, Nature, 489, 519, 10.1038/nature11404

2014, Comprehensive molecular characterization of urothelial bladder carcinoma, Nature, 507, 315, 10.1038/nature12965

2014, Comprehensive molecular profiling of lung adenocarcinoma, Nature, 511, 543, 10.1038/nature13385

Terheyden, 2010, Response to imatinib mesylate depends on the presence of the V559A-mutated KIT oncogene, J. Invest. Dermatol., 130, 314, 10.1038/jid.2009.197

Topalian, 2012, Safety, activity, and immune correlates of anti-PD-1 antibody in cancer, N. Engl. J. Med., 366, 2443, 10.1056/NEJMoa1200690

Tsao, 2012, Melanoma: from mutations to medicine, Genes Dev., 26, 1131, 10.1101/gad.191999.112

Tumeh, 2014, PD-1 blockade induces responses by inhibiting adaptive immune resistance, Nature, 515, 568, 10.1038/nature13954

Van Allen, 2014, The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma, Cancer Discov., 4, 94, 10.1158/2159-8290.CD-13-0617

Watson, 2014, The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF, Cancer Res., 74, 4845, 10.1158/0008-5472.CAN-14-1232-T

Whittaker, 2013, A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition, Cancer Discov., 3, 350, 10.1158/2159-8290.CD-12-0470

Winnepenninckx, 2006, Gene expression profiling of primary cutaneous melanoma and clinical outcome, J. Natl. Cancer Inst., 98, 472, 10.1093/jnci/djj103